Drugs / DC/PC3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00345293 | Jun 2006 → Dec 2013 | prostate cancer | Rockefeller University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DC/PC3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00345293 ↗ |
| Action | Activate | “Dendritic cells are known to activate other immune cells such as T cells” NCT00345293 ↗ |
| Modality | Vaccine | “DC/PC3, a dendritic cell vaccine used as immunotherapy for prostate cancer” NCT00345293 ↗ |
| Route | Subcutaneous | “Administered Subcutaneously” NCT00345293 ↗ |